Overview

Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)

Status:
Completed

Trial end date:
2019-12-18

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the efficacy of filgotinib and lanraplenib (formerly GS-9876) in females with moderately-to-severely active cutaneous lupus erythematosus (CLE).

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences

Collaborator:

Galapagos NV